An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian Population

      We investigated whether an insulin-like growth factor I (IGF-I) promoter polymorphism is associated with excess mortality in elderly subjects with myocardial infarction (MI). This association was assessed in 7,983 subjects of the Rotterdam Study during 14 years of follow-up. Among 345 subjects who developed a MI, the risk of mortality was 1.49 times higher in the variant carriers of the IGF-I promoter polymorphism than in the nonvariant carriers (95% confidence interval 1.10 to 2.10, p = 0.02). The risk of death increased with the number of variant alleles. Our study suggests that genetically determined low IGF-I activity is an important determinant of mortality in subjects with MI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ren J.
        • Samson W.K.
        • Sowers J.R.
        Insulin-like growth factor I as a cardiac hormone.
        J Mol Cell Cardiol. 1999; 31: 2049-2061
        • Conti E.
        • Andreotti F.
        • Sciahbasi A.
        • Riccardi P.
        • Marra G.
        • Menini E.
        • Ghirlanda G.
        • Maseri A.
        Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction.
        J Am Coll Cardiol. 2001; 38: 26-32
        • Hong Y.
        • Pedersen N.L.
        • Brismar K.
        • Hall K.
        • de Faire U.
        Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins.
        J Clin Endocrinol Metab. 1996; 81: 1791-1797
        • Vaessen N.
        • Heutink P.
        • Janssen J.A.
        • Witteman J.C.
        • Testers L.
        • Hofman A.
        • Lamberts S.W.
        • Oostra B.A.
        • Pols H.A.
        • van Duijn C.M.
        A polymorphism in the gene for IGF-I.
        Diabetes. 2001; 50: 637-642
        • Rietveld I.
        • Janssen J.A.
        • van Rossum E.F.
        • Houwing-Duistermaat J.J.
        • Rivadeneria F.
        • Hofman A.
        • Pols H.A.
        • van Duijn C.M.
        • Lamberts S.W.
        A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height.
        Clin Endocrinol. 2004; 61: 195-203
        • Bleumink G.S.
        • Rietveld I.
        • Janssen J.A.M.J.L.
        • van Rossum E.F.C.
        • Deckers J.W.
        • Hofman A.
        • Witteman J.C.M.
        • van Duijn C.M.
        • Stricker B.H.C.
        Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study).
        Am J Cardiol. 2004; 94: 384-386
        • Li B.
        • Setoguchi M.
        • Wang X.
        • Andreoli A.M.
        • Leri A.
        • Malhotra A.
        • Kajstura J.
        • Anversa P.
        Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart.
        Circ Res. 1999; 84: 1007-1019